Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib

2010 ◽  
Vol 283 (1) ◽  
pp. 133-134 ◽  
Author(s):  
Houssam Oweini ◽  
Zaher K. Otrock ◽  
Rami A. R. Mahfouz ◽  
Ali Bazarbachi
2017 ◽  
Vol 2017 ◽  
pp. 1-3
Author(s):  
Sasha Mikhael ◽  
Ashlee Pascoe ◽  
Joseph Prezzato

The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) in reproductive-aged women poses major dilemmas concerning its associated teratogenicity as observed in many animal studies. Much controversy exists regarding continuation versus discontinuation of its use in pregnancy with some studies suggesting safety of TKIs before and during pregnancy and others reporting toxicity and adverse outcomes. TKIs have become a well-established treatment option for CML, significantly improving prognosis, and yet have been reported to be fetotoxic. We present a case of a 25-year-old woman who achieved successful pregnancy and delivery after withholding treatment, meanwhile relapsing, eventually achieving complete molecular remission after reinitiation of high dose dasatinib.


1992 ◽  
Vol 40 (3) ◽  
pp. 238-239 ◽  
Author(s):  
Michael Crump ◽  
Xing-Hua Wang ◽  
Matthew Sermer ◽  
Armand Keating

2009 ◽  
Vol 48 (16) ◽  
pp. 1433-1435 ◽  
Author(s):  
Motohiro Tsuzuki ◽  
Youko Inaguma ◽  
Kousuke Handa ◽  
Akio Hasegawa ◽  
Yukiya Yamamoto ◽  
...  

2010 ◽  
Vol 2010 ◽  
pp. 1-4 ◽  
Author(s):  
Monika Conchon ◽  
Sabri S. Sanabani ◽  
Mariana Serpa ◽  
Mafalda M. Y. Novaes ◽  
Luciana Nardinelli ◽  
...  

Here we report the case of an 18-year-old woman with chronic myeloid leukemia (CML) who became pregnant while undergoing treatment with dasatinib. Before pregnancy, she received imatinib mesylate therapy but could not tolerate the treatment. The regimen was then changed to dasatinib at a dose of 70 mg b.i.d. While she was in hematological remission and on dasatinib therapy, she became pregnant. The unplanned pregnancy was identified after the patient had experienced four weeks of amenorrhea. Because the patient elected to continue the pregnancy to term, dasatinib was stopped immediately. Meanwhile, CML hematological relapse occurred and then she was treated with interferon- (IFN-) (9 million IU/day) throughout the pregnancy without a complete hematological response. She successfully gave birth to a male baby at 33 weeks by cesarean section delivery with no sequelae or malformations. Although this experience is limited to a single patient, it provides a useful contribution for counselling patients inadvertently exposed to dasatinib during pregnancy.


2011 ◽  
Vol 61 (5) ◽  
pp. 565-566 ◽  
Author(s):  
Joydeb Roychowdhury ◽  
Maitreyee Bhattacharyya ◽  
Arup Kumar Kundu ◽  
Madhavi Panfalia

Sign in / Sign up

Export Citation Format

Share Document